A Phase I Comparative Study of Pharmacokinetics, Safety, and Efficacy of RPH-002 and Erbitux® in Unresectable Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma

NCT07435311 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

118

Enrollment

INDUSTRY

Sponsor class

Conditions

Head and Neck Squamous Cell Carcinoma

Interventions

DRUG: RPH-002
DRUG: Erbitux®
DRUG: cisplatin
DRUG: docetaxel

Sponsor

R-Pharm